DD-02 PHARMACODYNAMIC BIOMARKER ASSESSMENTS IN A PHASE I/II TRIAL OF THE HYPOXIA-ACTIVATED PRODRUG TH-302 AND BEVACIZUMAB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

BACKGROUND: Glioblastoma (GBM) remains an incurable malignancy with rapid progression and poor survival. GBM exhibits a hypoxic nature, and treatment with bevacizumab (BEV) may increase intratumoral hypoxia. TH-302 is an investigational prodrug that selectively releases the DNA cross-linker (Br-IPM)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Cavazos, David, Gruslova, Aleksandra, Sun, J., Floyd, John R., Fichtel, Lisa, Tadi, Surendar, Lodi, Alessia, Tiziani, Stefano, Hart, C.P., Eng, Clarence, Brenner, Andrew
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218032/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou246.2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items